218 related articles for article (PubMed ID: 18663308)
1. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
[TBL] [Abstract][Full Text] [Related]
2. Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy.
Denton AB; Tsaparas Y
Otolaryngol Head Neck Surg; 2007 Apr; 136(4):563-7. PubMed ID: 17418252
[TBL] [Abstract][Full Text] [Related]
3. High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy.
Pignatti M; Pedone A; Baccarani A; Guaraldi G; Orlando G; Lombardi M; De Santis G
Aesthetic Plast Surg; 2012 Feb; 36(1):180-5. PubMed ID: 21717261
[TBL] [Abstract][Full Text] [Related]
4. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
[TBL] [Abstract][Full Text] [Related]
5. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.
Silvers SL; Eviatar JA; Echavez MI; Pappas AL
Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):34S-45S. PubMed ID: 16936543
[TBL] [Abstract][Full Text] [Related]
6. Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.
Pavicic T; Ruzicka T; Korting HC; Gauglitz G
J Drugs Dermatol; 2010 Jun; 9(6):690-5. PubMed ID: 20645533
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus.
Carruthers A; Carruthers J
Dermatol Surg; 2008 Nov; 34(11):1486-99. PubMed ID: 18811715
[TBL] [Abstract][Full Text] [Related]
8. Patient Reported Outcomes from HIV Facial Lipoatrophy Treatment With a Volumizing Hyaluronic Acid Filler: A Prospective, Open-Label, Phase I and II Study.
Ho D; Jagdeo J
J Drugs Dermatol; 2016 Sep; 15(9):1064-9. PubMed ID: 27602967
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of a Volumizing Hyaluronic Acid Filler for Treatment of HIV-Associated Facial Lipoatrophy.
Ho D; Jagdeo J
JAMA Dermatol; 2017 Jan; 153(1):61-65. PubMed ID: 27806168
[TBL] [Abstract][Full Text] [Related]
10. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
Loutfy MR; Raboud JM; Antoniou T; Kovacs C; Shen S; Halpenny R; Ellenor D; Ezekiel D; Zhao A; Beninger F
AIDS; 2007 May; 21(9):1147-55. PubMed ID: 17502725
[TBL] [Abstract][Full Text] [Related]
11. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
[TBL] [Abstract][Full Text] [Related]
12. A comparison of lipoatrophy and aging: volume deficits in the face.
Coleman S; Saboeiro A; Sengelmann R
Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
[TBL] [Abstract][Full Text] [Related]
14. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial to determine the influence of laser therapy, monopolar radiofrequency treatment, and intense pulsed light therapy administered immediately after hyaluronic acid gel implantation.
Goldman MP; Alster TS; Weiss R
Dermatol Surg; 2007 May; 33(5):535-42. PubMed ID: 17451575
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of injectable CaHA for the treatment of mid-face volume loss.
Beer K; Yohn M; Cohen JL
J Drugs Dermatol; 2008 Apr; 7(4):359-66. PubMed ID: 18459517
[TBL] [Abstract][Full Text] [Related]
17. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone.
Orentreich D; Leone AS
Dermatol Surg; 2004 Apr; 30(4 Pt 1):548-51. PubMed ID: 15056149
[TBL] [Abstract][Full Text] [Related]
18. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
[TBL] [Abstract][Full Text] [Related]
19. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study.
Mole B; Gillaizeau F; Carbonnel E; Pierre I; Brazille P; Grataloup C; Mercier S; Duracinsky M; Weiss L; Piketty C
AIDS Res Hum Retroviruses; 2012 Mar; 28(3):251-8. PubMed ID: 21801082
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy.
Antoniou T; Raboud JM; Kovacs C; Diong C; Brunetta J; Smith G; Halpenny R; Beninger F; Loutfy MR
AIDS Care; 2009 Oct; 21(10):1247-52. PubMed ID: 20024700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
